Nature Reviews Cardiology

Article	Citations
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives	930
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions	567
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective	566
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	501
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control	365
Environmental determinants of cardiovascular disease: lessons learned from air pollution	349
Interplay between inflammation and thrombosis in cardiovascular pathology	340
Smart wearable devices in cardiovascular care: where we are and how to move forward	318
PPAR control of metabolism and cardiovascular functions	302
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	300
Global epidemiology of dyslipidaemias	287
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	279
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	278
Cardiac natriuretic peptides	256
Epidemiology of cardiovascular disease in Europe	235
Pathophysiology of sepsis-induced cardiomyopathy	234
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	230
Native and bioengineered extracellular vesicles for cardiovascular therapeutics	225
Global epidemiology of valvular heart disease	218
Transportation noise pollution and cardiovascular disease	208
Self-powered cardiovascular electronic devices and systems	200
Cellular and molecular pathobiology of heart failure with preserved ejection fraction	192
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6	184
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	178
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	171

Cardiovascular effects and safety of (non-aspirin) NSAIDs	167
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	162
Epicardial adipose tissue in contemporary cardiology	157
Ceramides and other sphingolipids as drivers of cardiovascular disease	155
Cardiovascular disease in patients with severe mental illness	154
Heart failure with mid-range or mildly reduced ejection fraction	153
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	150
The role of cardiac rehabilitation in improving cardiovascular outcomes	146
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	141
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment	139
Systems biology in cardiovascular disease: a multiomics approach	137
Lifestyle interventions for the prevention and treatment of hypertension	129
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	125
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity	125
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	123
Sit less and move more for cardiovascular health: emerging insights and opportunities	118
Epidemiology of the inherited cardiomyopathies	117
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	115
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management	113
Optical coherence tomography in coronary atherosclerosis assessment and intervention	108
Pregnancy and cardiovascular disease	104
Genomics of hypertension: the road to precision medicine	98
Cardiac optogenetics: a decade of enlightenment	96
Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target	95
High-density lipoproteins, reverse cholesterol transport and atherogenesis	94
Genomic frontiers in congenital heart disease	90
Apolipoproteins in vascular biology and atherosclerotic disease	89
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	88
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	87
Blood pressure and its variability: classic and novel measurement techniques	85
Transforming growth factor-β in myocardial disease	84
Catheter ablation for atrial fibrillation: current indications and evolving technologies	81
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes	79
Device-based therapies for arterial hypertension	76
Applications of artificial intelligence in cardiovascular imaging	75
Cardiovascular risks of climate change	75
Mechanisms and consequences of endothelial cell senescence	73
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	71
Cardiac involvement in the long-term implications of COVID-19	71
Climate change and cardiovascular disease: implications for global health	71
Bleeding avoidance strategies in percutaneous coronary intervention	68
Myocardial stunning and hibernation revisited	67
RNA-targeting and gene editing therapies for transthyretin amyloidosis	66
Update on the pathophysiology and medical treatment of peripheral artery disease	65
Social determinants of atrial fibrillation	65
Vascular endothelial cell development and diversity	64
The role of mitochondrial fission in cardiovascular health and disease	64
Sulfide regulation of cardiovascular function in health and disease	63
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions	62
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	62

Clinical utility of polygenic risk scores for coronary artery disease	60
Branched-chain amino acids in cardiovascular disease	59
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	56
Epidemiology and prevention of venous thromboembolism	55
Immune cell profiling in atherosclerosis: role in research and precision medicine	53
Epidemiology and modifiable risk factors for atrial fibrillation	53
The evolving cardiac lymphatic vasculature in development, repair and regeneration	53
A fresh look at coronary microembolization	52
Targeted delivery of therapeutic agents to the heart	52
Obesity and the risk of cardiometabolic diseases	52
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications	50
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs	50
Pharmacogenetics to guide cardiovascular drug therapy	50
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	49
Prevention of atherosclerosis from childhood	48
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies	47
The health digital twin: advancing precision cardiovascular medicine	46
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	46
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia	42
Targeting the sarcomere in inherited cardiomyopathies	42
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management	41
Electroimmunology and cardiac arrhythmia	39
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	38
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism	38
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	38
The COVID-19 pandemic: a catalyst to improve clinical trials	36
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	36
Stroke prevention strategies in high-risk patients with atrial fibrillation	36
Remote monitoring and digital health tools in CVD management	35
Increasing representation and diversity in cardiovascular clinical trial populations	35
Towards precision medicine in heart failure	35
Obstructive sleep apnoea heterogeneity and cardiovascular disease	34
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	34
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	34
Coronary vessel formation in development and disease: mechanisms and insights for therapy	34
Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities	33
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets	33
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention	32
The microtubule cytoskeleton in cardiac mechanics and heart failure	31
Macrophages in cardiac remodelling after myocardial infarction	30
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease	30
Hallmarks of cardiovascular ageing	30
Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options	29
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research	29
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	29
Mechanisms by which angiotensin-receptor blockers increase ACE2 levels	29
The oral microbiome in the pathophysiology of cardiovascular disease	27
Cardiac fibroblasts and mechanosensation in heart development, health and disease	27
Improving clinical practice guidelines with implementation science	25
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome	25
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer	25
The contribution of the exposome to the burden of cardiovascular disease	24
Calcific aortic valve disease: mechanisms, prevention and treatment	24
A change of heart: new roles for cilia in cardiac development and disease	24
Effects of fatty acids on T cell function: role in atherosclerosis	24
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease	23
Hypertension in China: epidemiology and treatment initiatives	23
Single-cell transcriptomics for the assessment of cardiac disease	23
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	23
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure	23
Reduced hospital admissions for ACS — more collateral damage from COVID-19	23
Flow-induced reprogramming of endothelial cells in atherosclerosis	22
Temporary mechanical circulatory support devices: practical considerations for all stakeholders	21
The need for increased pragmatism in cardiovascular clinical trials	21
The use of new CRISPR tools in cardiovascular research and medicine	21
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	21
Plastics and cardiovascular disease	20
Pathophysiology and risk factors of peripartum cardiomyopathy	20
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	19
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease	19
Genetics and mechanisms of thoracic aortic disease	19
Diversity 4.0 in the cardiovascular health-care workforce	18
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	18
Interventional therapies for pulmonary embolism	18
Long COVID and cardiovascular disease: a learning health system approach	17
Clarification of the definition of hypoplastic left heart syndrome	17
Non-hyperaemic coronary pressure measurements to guide coronary interventions	16
Genomic enhancers in cardiac development and disease	16
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	16
Cardiovascular health and disease in migrant populations: a call to action	16

Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention	16
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group	16
PCSK9-targeted therapies: present and future approaches	16
RAAS inhibitors do not increase the risk of COVID-19	16
The role of aldehyde dehydrogenase 2 in cardiovascular disease	16
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	15
Developing a vaccine against atherosclerosis	15
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death	15